Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Namwiwat Medical PCLBKK:NAM +3.68%37 3-Year EBITDA Growth Rate is -1.60% as of Jun. 2026. GuruFocus rates BKK:NAM with a GF Score™ of 37/100 and a GF Value™ of ฿5.83 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 688 Medical Devices & Instruments companies, Namwiwat Medical PCL ranks worse than 66.42% on this metric.
During the past 12 months, Namwiwat Medical PCL's average EBITDA Per Share Growth Rate was -32.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -1.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Namwiwat Medical PCL was 3.90% per year. The lowest was -1.60% per year. And the median was 1.15% per year.
Namwiwat Medical PCL (BKK:NAM) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Namwiwat Medical PCL 3-Year EBITDA Growth Rate Related Terms
BKK:NAM vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Namwiwat Medical PCL's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Namwiwat Medical PCL 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Namwiwat Medical PCL's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Namwiwat Medical PCL's 3-Year EBITDA Growth Rate falls into.
Namwiwat Medical PCL 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -1.60% mean?
Namwiwat Medical PCL (BKK:NAM) has a 3-Year EBITDA Growth Rate of -1.60% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Namwiwat Medical PCL and its competitors. According to the industry distribution chart, Namwiwat Medical PCL ranks #457 out of 688 companies in the Medical Devices & Instruments industry, placing it in the top 66.4%.
Is Namwiwat Medical PCL's 3-Year EBITDA Growth Rate too high?
Namwiwat Medical PCL's current 3-Year EBITDA Growth Rate is -1.60%. Based on the distribution chart, Namwiwat Medical PCL ranks #457 out of 688 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Namwiwat Medical PCL has a GF Score™ of 37/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Namwiwat Medical PCL's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Namwiwat Medical PCL ranks #457 out of 688 companies for 3-Year EBITDA Growth Rate. This places Namwiwat Medical PCL in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Namwiwat Medical PCL and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Namwiwat Medical PCL's current 3-Year EBITDA Growth Rate is -1.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Namwiwat Medical PCL stock overvalued right now?
Based on GuruFocus' analysis, Namwiwat Medical PCL (BKK:NAM) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿5.83, compared to a current price of ฿3.38 — trading 42% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -1.60%. Namwiwat Medical PCL's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Namwiwat Medical PCL (BKK:NAM), the current 3-Year EBITDA Growth Rate is -1.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Namwiwat Medical PCL (BKK:NAM) Overvalued in 2026?
Based on GuruFocus' analysis, Namwiwat Medical PCL stock appears to be undervalued.
The current stock price of ฿3.38 is trading 42% below its estimated GF Value™ of ฿5.83.
GuruFocus considers Namwiwat Medical PCL to be Significantly Undervalued.
Key valuation signals for BKK:NAM:
3-Year EBITDA Growth Rate: -1.60%
GF Value™: ฿5.83 vs. price of ฿3.38 (42% below fair value)
No single metric tells the full story. See the BKK:NAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Namwiwat Medical Corp PCL operates a manufacturing business, importing and distributing Medical tools and equipment for cleaning and disinfecting medical equipment in hospitals and nursing homes in accordance with public health standards. The Group has a total of three reporting segments as follows: Medical equipment manufacturing and distribution segment; Medical supplies manufacturing and distribution segment; CSSD disinfection Medical equipment maintenance services segment, and waste services segment. The Group operates its business in one geography, only in Thailand.
37GF Score
Get the complete analysis for BKK:NAM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:NAM has been successfully added to your 
